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 Which patients benefi t from 
lowering LDL to <100 mg/dL?
EVIDENCE-BASED ANSWER
A
 
 patients who have coronary
 heart disease (CHD) or are 
at high risk for CHD should aim for a 
low-density lipoprotein (LDL) target of 
<100 mg/dL. An LDL target of <70 mg/dL
is an option for very-high-risk patients 
(strength of recommendation [SOR]: C, 
expert opinion). 
Th e evidence also indicates that high-
risk patients benefi t from a statin—pref-
erably in high doses—regardless of their 
baseline LDL or degree of LDL reduction 
with treatment (SOR: A, a large randomized 
controlled trial [RCT] and meta-analyses).  
Evidence summary  
Th e National Cholesterol Expert Panel (NCEP) 
on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults defi nes high-
risk patients as having known CHD, diabetes, 
noncoronary atherosclerotic disease, or multi-
ple risk factors for CHD.1 (Moderate- or low-risk 
patients are defi ned as having a 10-year risk of 
CHD <20%.) Th e National Kidney Foundation 
Kidney Disease Outcomes Quality Initiative 
(K/DOQI) also includes in the high-risk group 
patients with stage 5 kidney disease (glomerular 
fi ltration rate <15 mL/min or on dialysis).2 
Th e NCEP goes on to defi ne very-high-
risk patients as those with known CHD and 
multiple risk factors. Th ese risks include 
acute coronary syndrome, diabetes, metabol-
ic syndrome, or poorly controlled or severe 
risk factors, especially cigarette smoking.1 
An LDL target of <100 mg/dL for high-
risk patients and an optional target of 
<70 mg/dL for very-high-risk patients were 
determined by expert interpretation of evi-
dence from large trials and meta-analyses of 
a log-linear relationship between LDL levels 
and CHD risk (TABLE).3,4  
Lowering LDL reduces fi rst coronary 
events in high-risk patients
A large 2005 meta-analysis pooled 90,056 
high-risk patients in 14 trials of statin use 
compared with placebo (11 studies), no treat-
ment (1 study), very-low-dose statin use (1 
study), or usual care (1 study). Primary out-
comes were a change in LDL cholesterol, 
all-cause mortality, CHD mortality, and non-
CHD mortality.5 
Th e meta-analysis showed that high-risk 
patients had a 21% reduction in the 5-year 
incidence of fi rst major coronary events for 
every 39 mg/dL decrease in LDL cholesterol 
(relative risk [RR]=0.79; 95% confi dence in-
terval [CI], 0.77-0.81; number needed to treat 
[NNT]=27). A subanalysis of 447 high-risk pa-
tients with LDL levels <100 mg/dL at baseline 
found that the risk of major coronary events 
decreased with statin therapy, but the 99% CI 
included 1 (RR=0.75; 99% CI, 0.56-1.01).5
 
 Simvastatin decreases MI and stroke 
regardless of baseline LDL
One RCT included in the meta-analysis war-
rants special attention. Th is study evaluated 
the use of simvastatin 40 mg daily compared 
with placebo for 5 years in 20,536 high-risk 
patients who were grouped according to ini-
tial LDL level (<115 mg/dL, 115-135 mg/dL, 
and >135 mg/dL). Simvastatin lowered the 
average patient’s LDL by 39 mg/dL (no CIs 
provided).6 
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Regardless of the baseline LDL, simvas-
tatin decreased the rate of fi rst myocardial 
infarction (MI), stroke, or need for revascu-
larization compared with placebo (RR=0.76; 
95% CI, 0.72-0.81; NNT=18). Subgroup analy-
sis of 3421 high-risk patients with LDL levels 
<100 mg/dL at baseline showed fewer major 
coronary events with simvastatin than with 
placebo (RR=0.78; 95% CI, 0.68-0.90).6  
High-dose statins decrease MI 
more than standard doses
A 2008 meta-analysis of 29,395 high-risk 
patients in 7 trials examined high-dose com-
pared with standard statin use for secondary 
prevention. Six trials used atorvastatin 80 mg 
daily as the high-dose regimen; 1 trial used 
simvastatin 80 mg daily. Th e standard regi-
mens were 5 to 40 mg of pravastatin, simvas-
tatin, atorvastatin, or lovastatin. 
Th e weighted mean diff erence of 
LDL lowering between the 2 groups was 
28 mg/dL (95% CI, 23-32 mg/dL), and fewer 
than 50% of patients achieved the treatment 
target (LDL <80 mg/dL). Nevertheless, in-
tensive statin use decreased MIs compared 
with standard dosing (RR=0.83; 95% CI, 
0.77-0.91).7 
Th is meta-analysis included a key RCT, 
which enrolled 4162 high-risk patients and 
compared pravastatin 40 mg (standard 
therapy) with atorvastatin 80 mg (intensive 
TABLE
Target LDL measurements for high-risk 
and very-high-risk patients1,2,7,8  
Risk level Risk factors Goal LDL
High Known CHD 
OR 
Noncoronary atherosclerotic disease: abdominal aortic 
aneurysm, peripheral arterial disease, symptomatic carotid 
stenosis
OR
Stage 5 kidney disease (GFR <15 mL/min or on dialysis)
OR 
Diabetes
OR
≥2 of the following risk factors with 10-y risk of CHD >20%:
•  Cigarette smoking
•   Hypertension (BP >140/90 mm Hg or on antihypertensive 
medication)
•  Low HDL cholesterol (<40 mg/dL)
•   Family history of premature CHD (in male fi rst-degree 
relative <55 y; in female fi rst-degree relative <65 y)
•  Age (men >45 y; women >55 y)
  <100 mg/dL
Very high Known CHD
AND
Multiple major risk factors:
•  Acute coronary syndrome
•  Diabetes
•  Metabolic syndrome
•   Poorly controlled or severe risk factors, especially cigarette 
smoking
(Optional) 
<70 mg/dL
BP, blood pressure; CHD, coronary heart disease; GFR,glomerular fi ltration rate; HDL, high-density lipoprotein; 
LDL,low-density lipoprotein. 
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A target LDL 
of <70 mg/dL 
is an option for 
very-high-risk 
patients.
therapy) over an average of 24 months. Th e 
pravastatin group achieved a median LDL of 
95 mg/dL and the atorvastatin group achieved 
a median LDL of 62 mg/dL. Th e atorvastatin 
group had fewer deaths from any cause or a 
major cardiovascular event (RR=0.85; 95% CI, 
0.76-0.95; NNT=25).8
Does benefi t result from lower LDL, 
or some other statin effect?
Since most lipid studies have been done us-
ing a statin as the sole treatment agent, it is 
unclear whether patients benefi t more from 
a lower LDL or from some eff ect of the statin 
medication class.9 Statins reduce the risk of 
cardiovascular events in patients with an el-
evated C-reactive protein,10 perhaps indicat-
ing an anti-infl ammatory eff ect. However, 
fi brates and niacin have also been shown 
to decrease coronary events in high-risk 
patients in a few studies.11,12
Recommendations   
Th e NCEP Adult Treatment Panel III guide-
lines recommend treating high-risk patients 
to a target LDL of <100 mg/dL.
1
 A target LDL 
of <70 mg/dL is optional for very-high-risk 
patients (TABLE).1,3
Th e K/DOQI recommends that patients 
with stage 5 kidney disease be treated according 
to the NCEP guidelines for high-risk patients.2
Th e expected release date for the NCEP Adult 
Treatment Panel IV guidelines is fall 2011.13 JFP
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